Search Results for "Flt Pet"
Original Source: 18F-FLT-PET in Breast Cancer
This study will determine the correlation between the change in an immunohistochemical marker of cell proliferation (Ki-67) and the change in tumor 18F-FLT (3'-deoxy-3'[18F]-fluorothymidine) uptake in patients with breast cancer following treatment with standard of care neo-adjuvant therapy.
Prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostate ca...
BioPortfolio is an internet agent for Visiongain's life science, medical devices and pharmaceutical conference.
Swine flu is the common name given to a relatively new strain of influenza (flu) that caused a flu pandemic in 2009-2010. It is also referred to as H1N1 influenza (because it is the H1N1 strain of...
College Hill is a growing international business communications consultancy with offices in Europe, China, India, South Africa and the United States. College Hill's wide range of complementar...
Since 1983, Management Forum have built a reputation on providing the highest quality conference, seminar and knowledge-based experiences for leading professionals in some of the world's most...
A fact sheet about research on the risk of developing cancer of the breast, cervix, liver, and ovary from the use of oral contraceptives.
Novartis is working to expand its offering in emerging markets including Brazil, Russia, India and China.
The challenges of developing products in rare diseases are many - but no obstacle for Novartis Development teams.
As World TB Day on March 24 raises global awareness, Novartis remains a committed partner in the struggle.
With declining efficacy and resistance to existing sheep worm treatments on the rise, Novartis Animal Health worked together with sheep farmers and veterinarians to develop an unparalleled new treatme...
April 25 is World Malaria Day, an opportunity to reflect on the progress made in finding sustainable solutions for malaria.
Scientists who developed Novartis Coartem® and Glivec® receive 2009 "European Inventor of the Year" awards.
World leaders are focused on climate change and Novartis is, too. Our cutting-edge energy efficiency strategy is a driving long-term success for the environment and for our business.